Concepedia

Eric M. Parker

EM

90

Publications

7K

Citations

47

H-Index

1982

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

AGCO (United Kingdom)

Bristol-Myers Squibb (United States)

LabCorp (United States)

Eric M. Parker is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1982–2021

90

Publications

90

Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation

Gwendolyn T. Wong, Denise Manfra, Frederique M. Poulet et al. · Journal of Biological Chemistry · 2004 · 715 citations · Full text

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 407 citations

, , +20

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Matthew Fell, Christian Mirescu, Kallol Basu et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 326 citations · Full text

Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells.

Eric M. Parker, Kimihiko Kameyama, Tsutomu Higashijima et al. · Journal of Biological Chemistry · 1991 · 283 citations · Full text

Chimeric muscarinic cholinergic: beta-adrenergic receptors that activate Gs in response to muscarinic agonists.

Sui‐Lam Wong, Eric M. Parker, Elliott M. Ross · Journal of Biological Chemistry · 1990 · 230 citations · Full text

, , +20

Rows per page

1–5 of 90